Cerebyx Solution For Injection 75Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Cerebyx: Solution for injection (75mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

FOSPHENYTOIN (fos FEN i toyn) is used to control seizures in certain types of epilepsy. It can help to prevent seizures occurring during or after surgery.

In-Depth Information
Select a Medication

Cerebyx 100mg PE/2ml Solution for Injection

NDC: 000714007
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Status Epilepticus, Seizure Prophylaxis, Tonic-clonic Seizures, Partial Seizures

Storage Information
Refrigerate (between 36 and 46 degrees F)
Product should not be stored at room temperature for more than 48 hours
Discard product if it contains particulate matter, is cloudy, or discolored
Cerebyx 100mg PE/2ml Solution for Injection

Reported Side Effects for Cerebyx 100mg PE/2ml Solution for Injection

Bruise Incidence:
<7.3%*
Severity: MILD
Onset: DELAYED
Chills Incidence:
0.1-1.0%*
Severity: MILD
Onset: RAPID
Brain Bruise Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Breathing Difficulties Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: RAPID
Decreased Breathing Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Unable To Speak Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Loss Of Memory Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Restlessness Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Fainting Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Tenesmus Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Brain Attack Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: EARLY
Convulsions Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Long Qt Syndrome Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: RAPID
Psychosis Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Inceased Urination Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Collapsed Lung Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: EARLY
Muscle Disease Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Muscle Cramps Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Pain Of The Urethra Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Low White Blood Cell Counts Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
High White Blood Cells Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Infection Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Feeling Sick Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Rash With Pustules Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Large Pupil Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Rapid Muscle Twitches Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Ear Pain Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Rapid Heart Rate Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Injection Site Reaction Incidence:
>0.1%*
Severity: MILD
Onset: RAPID
Hypoxia Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Low Muscle Tone Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Overbreathing Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Parosmia Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Hyperkinesis Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Hyperacusis Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Red Spotted Rash Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Hostility Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Photosensitivity Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Coughing Up Blood Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Deafness Incidence:
0.1-2.2%*
Severity: SEVERE
Onset: DELAYED
Kidney Failure Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Emotional Lability Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Rhinitis Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Cyanosis Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: EARLY
Skin Discoloration Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Conjunctivitis Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Confusion Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Migraine Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Brain Infection Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Inability To Sleep Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Bowel Obstruction Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Low Phosphate Level Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Extra Saliva Production Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
High Potassium Level Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Excessive Sweating Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Heart Failure Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Inflamed Stomach Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Gas Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Nose Bleed Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Swelling Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Painful Urination Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Shortness Of Breath Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Upset Stomach Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Diabetes Insipidus Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Depression Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Dehydration Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Cough Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Allergic Skin Reaction Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Coma Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: EARLY
Swelling Of The Brain Incidence:
0.1-2.2%*
Severity: SEVERE
Onset: EARLY
Suddenly Stopped Heart Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: EARLY
Slow Heart Beat Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: RAPID
Irregular Heart Rate Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: EARLY
Joint Pain Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Decreased Appetite Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Anemia Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Light Sensitivity Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Retaining Urine Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Protein In The Urine Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Difficulty Swallowing Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Blood Clot In Lung Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Sinus Infection Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Sore Throat Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Postural Low Blood Pressure Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Bundle-branch Block Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Low Platelet Count Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Decreased Urination Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: EARLY
Brain Dysfunction Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Intestinal Bleeding Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Eye Pain Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Increased Blood Sugar Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Muscle Pain Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Vaginal Infection Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Uncontrolled Urination Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Hives Incidence:
0.1-1.0%*
Severity: MILD
Onset: RAPID
Muscle Weakness Incidence:
>1.0%*
Severity: MODERATE
Onset: DELAYED
Constipation Incidence:
>1.0%*
Severity: MODERATE
Onset: DELAYED
Skin Rash Incidence:
>1.0%*
Severity: MILD
Onset: EARLY
Fever Incidence:
>1.0%*
Severity: MILD
Onset: EARLY
Hypoesthesia Incidence:
>1.0%*
Severity: MILD
Onset: DELAYED
Overactive Reflexes Incidence:
>1.0%*
Severity: MODERATE
Onset: DELAYED
High Blood Pressure Incidence:
>1.0%*
Severity: MODERATE
Onset: EARLY
Low Potassium Levels Incidence:
>1.0%*
Severity: MODERATE
Onset: DELAYED
Metallic Taste Incidence:
1.0-3.3%*
Severity: MILD
Onset: EARLY
Dysarthria Incidence:
1.0-2.2%*
Severity: MODERATE
Onset: DELAYED
Weakness Incidence:
2.2-3.9%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
2.2-8.9%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
2.2-2.8%*
Severity: MILD
Onset: EARLY
Back Pain Incidence:
2.2%*
Severity: MILD
Onset: DELAYED
Hyperesthesia Incidence:
2.2%*
Severity: MODERATE
Onset: DELAYED
Rapid Heart Rate Incidence:
2.2%*
Severity: MODERATE
Onset: RAPID
Balance Problems Incidence:
2.2%*
Severity: MILD
Onset: EARLY
Lazy Eye Incidence:
2.2%*
Severity: MODERATE
Onset: DELAYED
Itching Incidence:
2.8-48.9%*
Severity: MILD
Onset: RAPID
Decreased Reflexes Incidence:
2.8%*
Severity: MILD
Onset: DELAYED
Distressed Incidence:
3.3%*
Severity: MILD
Onset: EARLY
Shaking Incidence:
3.3-9.5%*
Severity: MILD
Onset: EARLY
Double Vision Incidence:
3.3%*
Severity: MILD
Onset: EARLY
Paresthesias Incidence:
3.9-4.4%*
Severity: MILD
Onset: DELAYED
Pelvic Pain Incidence:
4.4%*
Severity: MILD
Onset: DELAYED
Dry Mouth Incidence:
4.4%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
4.5-8.9%*
Severity: MILD
Onset: EARLY
Lightheadedness Incidence:
5.0-31.1%*
Severity: MILD
Onset: EARLY
Peripheral Vasodilation Incidence:
5.6%*
Severity: MODERATE
Onset: RAPID
Drowsiness Incidence:
6.7-20.0%*
Severity: MILD
Onset: EARLY
Low Blood Pressure Incidence:
7.7%*
Severity: MODERATE
Onset: RAPID
Incoordination Incidence:
8.4-11.1%*
Severity: MODERATE
Onset: DELAYED
Ringing In Ears Incidence:
8.9%*
Severity: MILD
Onset: DELAYED
Gingival Hyperplasia Incidence:
>15.0%*
Severity: MODERATE
Onset: DELAYED
Fast Eye Movements Incidence:
15.1-44.4%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Cerebyx 100mg PE/2ml Solution for Injection

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Major Lifestyle Interaction
Alcohol and Cerebyx 100mg PE/2ml Solution for Injection(Fosphenytoin Sodium)
Alcohol and Hydantoins(Fosphenytoin Sodium)
You should avoid alcoholic beverages while taking Phenytoin. Alcohol can affect seizure control and interfere with the drug treatment, and may increase the risk of serious side effects. Decreased alertness, drowsiness, falls, or other side effects may occur. Do not drive or operate machinery if you are drinking alcohol-containing beverages. If you notice slurred speech, confusion, severe weakness, or difficulty breathing, contact your health care provider immediately.
Moderate Lifestyle Interaction
Marijuana and Cerebyx 100mg PE/2ml Solution for Injection(Fosphenytoin Sodium)
Marijuana and Fosphenytoin(Fosphenytoin Sodium)
Taking these drugs together can increase the risk fo side effects from Marijuana, Medical. You may feel drowsy or more tired. Do not drive or operate machinery until you know how these drugs affect you. Contact your health care provider immediately if you notice slurred speech, confusion, increases heart rate, or palpitations while taking Marijuana, Medical.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Cerebyx

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5